Skip to content

News

Study Finds Intraperitoneal Chemotherapy Underutilized

Study Finds Intraperitoneal Chemotherapy Underutilized

(August 4, 2015) A study published online in the Journal of Clinical Oncology reports that although the use of intraperitoneal chemotherapy (IP)/IV chemotherapy increased significantly at major cancer centers between 2003 and 2012, fewer than 50% of eligible patients received it. Previous studies have shown that the use of IP chemotherapy significantly improves survival among … Continued

Research

Partner Member Profile: Ovarian Cancer Alliance of Oregon a...

Partner Member Profile: Ovarian Cancer Alliance of Oregon and Southwest Washington

2015 marks the 10th anniversary of the Ovarian Cancer Alliance of Oregon and Southwest Washington, a Partner Member organization dedicated to spreading awareness through education, providing support to women and their families, and advocating for awareness and research funding. When Diane Rader O’Conner met Diane Elizondo while undergoing treatment for ovarian cancer, they realized the … Continued

Community

OCRF Research Finds Gene Therapy May Help Patients with Rec...

OCRF Research Finds Gene Therapy May Help Patients with Recurrent Ovarian Cancer

(July 30, 2015) Recurrent ovarian cancer patients have more hope today, thanks to OCRF-funded research by David Pepin, PhD at Massachusetts General Hospital. Dr. Pepin and his colleagues found that gene therapy that delivers a protein that suppresses the development of female reproductive organs may improve survival rates in patients with ovarian cancer that has … Continued

OCRA News

Younger Women with Low Grade Ovarian Cancer Face Worse Outc...

Younger Women with Low Grade Ovarian Cancer Face Worse Outcomes

(July 29, 2015) Research published online in the Journal of Clinical Oncology shows that upon completion of primary therapy, women with low-grade serous carcinoma of the ovary (LGSOC) or peritoneum (LGSPC) who are under the age of 35 and have persistent disease face worse outcomes. Researchers at the University of Texas MD Anderson Cancer Center … Continued

Research

OCRF Research Shows PARP/Immune Therapy Combo Shows Promise

OCRF Research Shows PARP/Immune Therapy Combo Shows Promise

(July 23, 2015) New OCRF-funded research demonstrates that combining a PARP-inhibitor with immune therapy results in tumor rejection and long-term survival in a mouse model of BRCA1-deficient ovarian cancer.  The study, published in Cancer Immunology Research, was funded by an OCRF Liz Tilberis Early Career Award to Sarah Adams, MD. The benefit of this combination … Continued

OCRA News

Comparison of Clear Cell and Serous Ovarian Cancer- Charact...

Comparison of Clear Cell and Serous Ovarian Cancer- Characteristics and Prognosis

(July 21, 2015) A group of Chinese researchers compared clinical characteristics and prognosis between ovarian clear cell carcinoma (CCC) and serous carcinoma (SC), and found that women with ovarian CCC presented at a younger age and early stage. Patients with ovarian CCC also had a longer time to recurrance, but they had similar overall survival … Continued

Research

QVC Heads to the Hamptons for Annual Charitable Broadcast

QVC Heads to the Hamptons for Annual Charitable Broadcast

QVC and Ovarian Cancer Research Fund Joining Forces for “QVC Presents Super Saturday LIVE” Broadcast WEST CHESTER, Pa. (July 21, 2015) – Help advance the fight against ovarian cancer with stylish steals and dazzling deals. QVC and Ovarian Cancer Research Fund (OCRF) are uniting once again for “QVC Presents Super Saturday LIVE,” an annual designer … Continued

Events

Body Mass Index Impacts Ovarian Cancer Chemotherapy Dosages

Body Mass Index Impacts Ovarian Cancer Chemotherapy Dosages

(July 19, 2015) Ovarian cancer patients who are overweight or obese are often given less chemotherapy per pound of body weight in order to reduce the toxic side effects associated with higher doses, and this in turn may lower their chances of survival, according to a study by researchers at the Rutgers Cancer Institute of … Continued

Research

NASCAR’s Martin Truex’s girlfriend Sherry Polle...

NASCAR’s Martin Truex’s girlfriend Sherry Pollex goes to Capitol Hill to advocate for affordable therapy costs, ovarian cancer research funding

NASCAR’s Martin Truex Jr.’s girlfriend Sherry Pollex goes to Capitol Hill to advocate for affordable therapy costs, ovarian cancer research funding Pollex, Ovarian Cancer National Alliance support Cancer Treatment Parity Act, to ensure affordable out-of-pocket costs for cancer therapy WASHINGTON, D.C. — Today Sherry Pollex, girlfriend to NASCAR’s Martin Truex Jr. and longtime champion of … Continued

Advocacy

Bevacizumab with Chemo Improves Survival in Ovarian Cancer ...

Bevacizumab with Chemo Improves Survival in Ovarian Cancer with Poor Prognosis

(July 1, 2015) When bevacizumab was added to standard chemotherapy, ovarian cancer patients with a poor prognosis had an overall survival benefit, according to the ICON7 study published online this week in journal The Lancet Oncology. The study enrolled 1,528 women with newly diagnosed ovarian cancer, high-risk early-stage disease or more advanced disease. The patients were … Continued

Research

Partner Member Profile: WNY Ovarian Cancer Project

Partner Member Profile: WNY Ovarian Cancer Project

When WNY Ovarian Cancer Project co-founder Kathleen Maxian was diagnosed with ovarian cancer, she felt overwhelmed by the amount of negative statistics and information she found on the internet. It took a long 6 months until she met a long-term ovarian cancer survivor who showed her survival was possible. Now a 6-year survivor, Kathleen says … Continued

Community

Stay Informed

Get email updates about research news, action alerts, and ways to join the fight.

We care about your data. Read our privacy policy.